Estrogen receptor subtype-specific effects on markers of bone homeostasis

Molecular and Cellular Endocrinology

Volumn 291, Issue 1-2, 2008, Pages 104-108

  Hertrampf, T ^a   Schleipen, B ^a   Velders, M ^a   Laudenbach, U ^a   Fritzemeier, K H ^b   Diel, P ^a  

^a Institut fur Kreislaufforschung und Sportmedizin   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Biochemical bone markers; Bone mineral density; Estrogen receptor alpha; Estrogen receptor beta; Estrogen receptor subtype specific agonists; estrogens

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LACTONE DERIVATIVE; OSTEOCALCIN; OSTEOPONTIN; PYRIDINOLINE; RECEPTOR SUBTYPE; TELOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE; BONE DENSITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HOMEOSTASIS; HORMONE ACTION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HOMEOSTASIS; MOLECULAR STRUCTURE; ORGAN SIZE; OVARIECTOMY; RANDOM ALLOCATION; RATS; UTERUS;

EID: 48449102834     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.03.003     Document Type: Article

References (49)

1. Allen M.J. Biochemical markers of bone metabolism in animals: uses and limitations. Vet. Clin. Pathol. 32 3 (2003) 101-113 (review)
2. Blair J.M., Zheng Y., and Dunstan C.R. RANK ligand. Int. J. Biochem. Cell Biol. 39 6 (2007) 1077-1081 (review)
3. Bland R. Steroid hormone receptor expression and action in bone. Clin. Sci. (Lond.) 98 2 (2000) 217-240 (review)
4. Bord S., Horner A., Beavan S., and Compston J. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J. Clin. Endocrinol. Metab. 86 5 (2001) 2309-2314
5. Bryant H.U., Glasebrook A.L., Yang N.N., and Sato M. An estrogen receptor basis for raloxifene action in bone. J. Steroid Biochem. Mol. Biol. 69 1-6 (1999) 37-44 (review)
6. Buckwalter J.A., Glimcher M.J., Cooper R.R., and Recker R. Bone biology. II. Formation, form, modeling, remodeling, and regulation of cell function. Instr. Course Lect. 45 (1996) 387-399 (review)
7. Butler W.T. The nature and significance of osteopontin. Connect. Tissue Res. 23 2-3 (1989) 123-136 (review)
8. Coleman R.E. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94 10 (2002) 2521-2533 (review)
9. Deftos L.J., Wolfert R.L., and Hill C.S. Bone alkaline phosphatase in Paget's disease. Horm. Metab. Res. 23 11 (1991) 559-561
10. Diez-Perez A. Selective estrogen receptor modulators (SERMS). Arq. Bras. Endocrinol. Metab. 50 4 (2006) 720-734
11. Diez J.L. Skeletal effects of selective oestrogen receptor modulators (SERMs). Hum. Reprod. Update 6 3 (2000) 255-258 (review)
12. Ebeling P.R., Peterson J.M., and Riggs B.L. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J. Bone Miner. Res. 7 11 (1992) 1243-1250
13. Fitzpatrick L.A. Estrogen therapy for postmenopausal osteoporosis. Arq. Bras. Endocrinol. Metabol. 50 4 (2006) 705-719 (review)
14. Girasole G., Jilka R.L., Passeri G., Boswell S., Boder G., Williams D.C., and Manolagas S.C. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89 3 (1992) 883-891
15. Gómez R., Magaña J.J., Cisneros B., Pérez-Salazar E., Faugeron S., Véliz D., Castro C., Rubio J., Casas L., and Valdés-Flores M. Association of the estrogen receptor alpha gene polymorphisms with osteoporosis in the Mexican population. Clin. Genet. 72 6 (2007) 574-581
16. Hadjidakis D.J., and Androulakis I.I. Bone remodeling. Ann. N.Y. Acad. Sci. 1092 (2006) 385-396 (review)
17. Hamdy N.A. Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. Curr. Opin. Investig. Drugs 8 4 (2007) 299-303 (review)
18. Hanson D.A., Weis M.A., Bollen A.M., Maslan S.L., Singer F.R., and Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 7 11 (1992) 1251-1258
19. Hegele-Hartung C., Siebel P., Peters O., Kosemund D., Muller G., Hillisch A., Walter A., Kraetzschmar J., and Fritzemeier K.H. Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc. Natl. Acad. Sci. U.S.A. 101 14 (2004) 5129-5134
20. Heine P.A., Taylor J.A., Iwamoto G.A., Lubahn D.B., and Cooke P.S. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc. Natl. Acad. Sci. U.S.A. 97 23 (2000) 12729-12734
21. Hertrampf T., Degen G.H., Kaid A.A., Laudenbach-Leschowsky U., Seibel J., Di Virgilio A.L., and Diel P. Combined effects of physical activity, dietary isoflavones and 17beta-estradiol on movement drive, body weight and bone mineral density in ovariectomized female rats. Planta Med. 72 6 (2006) 484-487
22. Hertrampf T., Gruca M.J., Seibel J., Laudenbach U., Fritzemeier K.H., and Diel P. The bone-protective effect of the phytoestrogen genistein is mediated via ERα-dependent mechanisms and strongly enhanced by physical activity. Bone 40 6 (2007) 1529-1535
23. Hillisch A., Peters O., Kosemund D., Muller G., Walter A., Schneider B., Reddersen G., Elger W., and Fritzemeier K.H. Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol. Endocrinol. 18 7 (2004) 1599-1609
24. Janckila A.J., Takahashi K., Sun S.Z., and Yam L.T. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin. Chem. 47 1 (2001) 74-80
25. Jordan V.C. Tamoxifen: catalyst for the change to targeted therapy. Eur. J. Cancer 44 1 (2008) 30-38
26. Kalu D.N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15 3 (1991) 175-191 (review)
27. Krassas G., and Papadopoulou E.P. Oestrogen action on bone cells. J. Musculoskelet. Neuronal Interact. 2 2 (2001) 143-151
28. Lee K., Jessop H., Suswillo R., Zaman G., and Lanyon L. Endocrinology: bone adaptation requires oestrogen receptor-alpha. Nature 424 6947 (2003) 389
29. Lerner U.H. Bone remodeling in post-menopausal osteoporosis. J. Dent. Res. 85 7 (2006) 584-595 (review)
30. Lindsay R., Hart D.M., Aitken J.M., MacDonald E.B., Anderson J.B., and Clarke A.C. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1 7968 (1976) 1038-1041
31. Lindberg M.K., Alatalo S.L., Halleen J.M., Mohan S., Gustafsson J.A., and Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. J. Endocrinol. 171 2 (2001) 229-236
32. Lindberg M.K., Erlandsson M., Alatalo S.L., Windahl S., Andersson G., Halleen J.M., Carlsten H., Gustafsson J.A., and Ohlsson C. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. J. Endocrinol. 171 3 (2001) 425-433
33. Lindberg M.K., Weihua Z., Andersson N., Movérare S., Gao H., Vidal O., Erlandsson M., Windahl S., Andersson G., Lubahn D.B., Carlsten H., Dahlman-Wright K., Gustafsson J.A., and Ohlsson C. Estrogen receptor specificity for the effects of estrogen in ovariectomized mice. J. Endocrinol. 174 2 (2002) 167-178
34. Lindberg M.K., Moverare S., Skrtic S., Alatalo S., Halleen J., Mohan S., Gustafsson J.A., and Ohlsson C. Two different pathways for the maintenance of trabecular bone in adult male mice. J. Bone Miner. Res. 17 4 (2002) 555-562
35. Morinobu M., Ishijima M., Rittling S.R., Tsuji K., Yamamoto H., Nifuji A., Denhardt D.T., and Noda M. Osteopontin expression in osteoblasts and osteocytes during bone formation under mechanical stress in the calvarial suture in vivo. J. Bone Miner. Res. 18 9 (2003) 1706-1715
36. Mueller S.O., and Korach K.S. Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. Curr. Opin. Pharmacol. 1 6 (2001) 613-619 (review)
37. Nakamura T., Imai Y., Matsumoto T., Sato S., Takeuchi K., Igarashi K., Harada Y., Azuma Y., Krust A., Yamamoto Y., Nishina H., Takeda S., Takayanagi H., Metzger D., Kanno J., Takaoka K., Martin T.J., Chambon P., and Kato S. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130 5 (2007) 811-823
38. Ohlsson C., Hellberg N., Parini P., Vidal O., Bohlooly M., Rudling M., Lindberg M.K., Warner M., Angelin B., and Gustafsson J.A. Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem. Biophys. Res. Commun. 278 3 (2000) 640-645
39. Parikka V., Peng Z., Hentunen T., Risteli J., Elo T., Väänänen H.K., and Härkönen P. Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice. Eur. J. Endocrinol. 152 2 (2005) 301-314
40. Pelzer T., Jazbutyte V., Hu K., Segerer S., Nahrendorf M., Nordbeck P., Bonz A.W., Muck J., Fritzemeier K.H., Hegele-Hartung C., Ertl G., and Neyses L. The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc. Res. 67 4 (2005) 604-612
41. Sato T., Shibata T., Ikeda K., and Watanabe K. Generation of bone-resorbing osteoclasts from B220 + cells: its role in accelerated osteoclastogenesis due to estrogen deficiency. J. Bone Miner. Res. 16 12 (2001) 2215-2221
42. Sodek J., Ganss B., and McKee M.D. Osteopontin. Crit. Rev. Oral Biol. Med. 11 3 (2000) 279-303 (review)
43. Sorensen M.G., Henriksen K., Dziegiel M.H., Tanko L.B., and Karsdal M.A. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol. 25 8 (2006) 475-483
44. Stevenson J.C. Hormone replacement therapy: review, update, and remaining questions after the Women's Health Initiative Study. Curr. Osteoporos. Rep. 2 1 (2004) 12-16 (review)
45. Syed F.A., Mödder U.I., Fraser D.G., Spelsberg T.C., Rosen C.J., Krust A., Chambon P., Jameson J.L., and Khosla S. Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J. Bone Miner. Res. 20 11 (2005) 1992-2001
46. Taranta A., Brama M., Teti A., De luca V., Scandurra R., Spera G., Agnusdei D., Termine J.D., and Migliaccio S. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 2 (2002) 368-376
47. Thiede M.A., Smock S.L., Petersen D.N., Grasser W.A., Thompson D.D., and Nishimoto S.K. Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology 135 3 (1994) 929-937
48. Windahl S.H., Vidal O., Andersson G., Gustafsson J.A., and Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J. Clin. Invest. 104 7 (1999) 895-901
49. Zaman G., Cheng M.Z., Jessop H.L., White R., and Lanyon L.E. Mechanical strain activates estrogen response elements in bone cells. Bone 27 2 (2000) 233-239